PlumX Metrics
Embed PlumX Metrics

Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid: A Possible Pitfall in 18F-FDG PET/CT

Clinical Nuclear Medicine, ISSN: 1536-0229, Vol: 47, Issue: 2, Page: 185-186
2022
  • 4
    Citations
  • 0
    Usage
  • 10
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

A 78-year-old man with multiple squamous cell carcinomas of the skin underwent 18F-FDG-PET/CT for restaging after 4 cycles of cemiplimab. The scan showed new disseminated FDG-avid skin lesions. Dermatologic examination and biopsy revealed bullous pemphigoid. Discontinuation of cemiplimab and treatment with corticosteroids led to clinical improvement, after which treatment with cemiplimab was resumed. A broad spectrum of inflammatory adverse events can occur in patients treated with immune checkpoint inhibitors, and FDG avidity of these lesions may mimic metastases. Knowledge of such imaging pitfalls is essential for interpreting 18F-FDG-PET/CT, particularly if they occur in the same organ as the primary tumor.

Bibliographic Details

Grünig, Hannes; Skawran, Stephan M; Nägeli, Mirjam; Kamarachev, Jivko; Huellner, Martin W

Ovid Technologies (Wolters Kluwer Health)

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know